RT Journal Article
SR Electronic
T1 End-of-Life Pain Medication among Cancer Patients in Hospice Settings
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6581
OP 6584
VO 34
IS 11
A1 LIISA KOIVU
A1 TUUKKA PÖLÖNEN
A1 TEIJA STORMI
A1 EEVA SALMINEN
YR 2014
UL http://ar.iiarjournals.org/content/34/11/6581.abstract
AB Cancer pain management in a hospice setting was studied in the present article. Drug treatments were studied at five time points: at the time of transfer to hospice, at 2nd day, two weeks, and two months following transfer to hospice care, as well as one day before death. Patients and Methods: Records of 138 consecutive cancer patients treated in hospice in 2010 were studied regarding the drugs given during their stay. The most common cancer was gastro-intestinal cancer (33%), followed by lung (16%) and breast cancer (11%). Data were collected from patients' records and coded in a validated manner for statistical analysis. Results: The median length of stay in hospice was 14 days (range=2-376 days). Upon transfer, 63% of patients were administered regularly-dosed opioids, 76.8% during the second day at hospice, and 89.9% of the patients received opioids one day prior to death. A significant change was observed in the more frequent subcutaneous administration during hospice stay (p<0.0001). Break-through pain was recorded on the second day in hospice by 52 % of patients, and by 76% on the day prior to death. Conclusion: Individual patients' needs determined the dose range, but this was not the case for administration route of strong opioids during hospice care.